UTHSCSA - Faculty Profiles

Search All | Profile | Publications | Grants | Faculty Index

Basler, MD, Joseph W

School of Medicine
Urology
(210) 567-5644
basler@uthscsa.edu

Dr. Baslers primary expertise is the diagnosis and treatment of urologic malignancies including tumors of the prostate, kidney, bladder, testis and male genitalia. He serves as primary consultant in the GU Tumor Clinic at the South Texas Audie L. Murphy VA Hospital. Other expertise includes Endourologic procedures, stone management, treatment of Peyronnies disease and general urology. Dr. Basler is the Principal Investigator of several Southwest Oncology Clinical Trials open at the UTHSCSA and STVAHCS campuses and serves on the national coordinating committee for a large VA Cooperative Trial in treatment of advanced prostate cancer. Dr. Basler also currently serves as President of Texas Urologic Society, representing over 400 member Urologists.

Appointments Education Expertise Teaching Publications Grants

9/2006 - Present

Thomas P. Ball Professor of Urology and Chief Section of Urology at South Texas VAHCS, Program Director in Urology

The University of Texas Health Science Center at San Antonio, Urology, San Antonio, TX

Journal Article

Montgomery B, Lavori P, Garzotto M, Lee K, Brophy M, Thaneemit-Chen S, Kelly W, Basler J, Ringer R, Yu W, Whittemore A, Lin DW, Basler, MD JW. Veterans Affairs Cooperative Studies Program Study 553: Chemotherapy After Prostatectomy, a Phase III Randomized Study of Prostatectomy Versus Prostatectomy with Adjuvant Docetaxel for Patients with High-Risk, Localized Prostate Cancer Urology 2008 Apr;.

Morey AF, Evans LA, McDonough RC, Park AM, Sexton WJ, Basler JW, Santucci RA, Amling CL, O''Reilly KJ. Evaluation of mechanical bowel preparation methods in urinary diversion surgery Can J Urol 2006 Oct;13(5):3250-3254.

Swanson G, Thompson I, Basler J, Crawford ED, Basler JW. Metastatic prostate cancer-does treatment of the primary tumor matter? J Urol 2006 Oct;176(4 Pt):1292-1298.

Swanson GP, Thompson IM, Basler J. Current status of lymph node-positive prostate cancer: incidence and predictors of outcome Cancer 2006 Jun;.

Basler JW. Efficacy of taxotere in the post-prostatectomy setting Curr Urol Rep 2006 May;7(3):165-165.

Brand TC, Hernandez J, Canby-Hagino ED, Basler JW, Thompson IM. Prostate cancer detection strategies Curr Urol Rep 2006 May;7(3):181-185.

Brand TC, Thibault GP, Basler JW. Dealing with non-cancerous findings on prostate biopsy Curr Urol Rep 2006 May;7(3):186-192.

Bruder JM, Ma JZ, Basler JW, Welch MD. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy Urology 2006 Jan;67(1):152-155.

Bruder JM, Ma JZ, Wing N, Basler J, Katselnik D. Effects of Alendronate on Bone Mineral Density in Men with Prostate Cancer Treated with Androgen Deprivation Therapy J Clin Densitometry 2006 Jan;9:431-437.

Thompson Jr IM, Bermejo CE, Hernandez J,Basler JW, Canby-Hagino ED. Screening for prostate cancer: opportunities and challenges Surg Oncol Clin N Am 2005 Oct;14(4):747-760.

Basler JW, Thompson Jr IM, Fernandes G, Hernandez J, Weiss GR, Troyer DA, Syad, S. The modulation of prostate cancer risk with alpha-tocopherol: a pilot randomized, controlled clinical trial J Urol 2005 Aug;174(2):519-522.

Basler JW, Jenkins C, Swanson GP:. Multidisciplinary management of prostate malignancy Curr. Urol. Rep 2005 May;6(3):228-234.

Basler JW, Jenkins C, Swanson G. Multidisciplinary management of prostate malignancy Curr Urol Rep 2005 May;6(3):228-234.

Mahal K, Hernandez J, Basler JW, Thompson IM. What''s new in the field of prostate cancer chemoprevention? Curr Urol Rep 2005 May;6(3):177-182.

Thompson Jr IM, Canby-Hagino ED, Swanson GP, Basler JW, Hernandez J, Crawford, ED. Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated? Curr Urol Rep 2005 Jan;6:183-189.

Thompson Jr IM, Hernandez J, Weiss GR, Troyer DA, Basler JW, Syed, S, Frenandes, G, von Merveldt, D. The modulation of prostate cancer risk with alpha - tocopherol: A pilot randomized, controlled clinical trial J Urology 2005 Jan;174:519-522.

Baillargeon JG, Pollock BH, Kristal, A, Bradshaw P, Hernandez J, Basler JW, Higgins, B, Lynch, S, Rozanski TA, Troyer DA, Thompson Jr IM. The association of body mass index and prostate specific antigen in a population-based study Cancer 2005 Jan;103:1092-1095.

Grizzle WE, Semmes OJ, Basler JW, Izbicka E, Feng Z, Kagan J, Adam BL, Troyer D, Srivastava S, Thornquist M, Zhang Z, Thompson IM. The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology Urol. Oncol 2004 Jul;22(4):337-343.

Mahal K, Hernandez J, Basler JW, Thompson IM. What''s new in the field of prostate cancer chemoprevention? Curr Oncol Rep 2004 May;6(3):237-242.

Thompson IM, Albanes D, Basler JW, Crawford ED, Denis LJ, Djavan B, Fleshner N, Johnson-Pais TL, Klein EA, Kristal AR, Lucia MS, Parnes HL, Piazza GA, Platz EA, Pollock BH, Price DK, Reichardt JK, Tangen CM, Tolcher AW, McMann MC. First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statement J Urol 2004 Feb;171(2 Pt):3-4.

Basler JW, Piazza GA. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention J Urol 2004 Feb;171(2 Pt):59-62.

Morey AF, McDonough RC, Evans LA, Sexton WJ, Basler JW, Santucci RA, O''Reilly KJ. Prospective multi-center randomized evaluation of mechanical bowel preparation methods in urinary diversion surgery Journal of Urology 2004 Jan;171:11-11.

Abstract

Hernandez J, Baillargeon J, Polock B,Basler JW,. The Association of Body Mass Index and Serum Prostate Specific antigen levels in a population-based study; 2005 May. (The Journal of Urology; vol. 173, no. 4).

Basler JW, Nunes WA, Chaudhuri TK. Lymphoscintigraphic mapping of the lymphatic drainage specific regions of the prostate; 2005 May. (The Journal of Urology; vol. 173, no. 4).

Chaudhuri TK, Basler JW, Latoni DE, Nunes WA, Smith HL. Lymphoscintigraphic Mapping of Lymphatic Drainage of the Prostate and Semina Vesicle; 2005 Jan. (J Nucl Med; vol. 46, no. 5).

Chaudhuri TK, Basler JW, Nunes W. Lymphoscintigraphic Mapping of the Lymphatic Drainage Specific Regions of the Prostate; 2004 Jan. (Proceedings of the American Urological Association Meeting).

Review Article

Basler, MD JW. Bladder Stones eMedicine 2008 Jan;.

Basler, MD JW. Colovesical Fistula eMedicine 2008 Jan;.

Basler, MD JW. Hemorrhagic Cystitis: Non-infectious eMedicine 2008 Jan;.

Editorial

Thompson Jr IM, Brand TC, Canby-Hagino ED, Basler JW, Troyer DA, Naylor SL, Leach RJ. Chemoprevention of prostate cancer Med Oncol Clinics of NA 2006 Jan;.

Electronic/Web Publication

Basler JW, Lucas J:. Non-infectious Hemorrhagic Cystitis[http://emedicine.com] 2005 Jan.

Not Specified

Sabichi AL, Lee JJ, Taylor RJ, Thompson IM, Miles BJ, Tangen CM, Minasian LM, Pisters LL, Caton JR, Basler JW, Lerner SP, Menter DG, Marshall JR, Crawford ED, Lippman SM. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study Clin Cancer Res 2006 Apr;12(7 Pt):2178-2184.

Thompson Jr IM, Brand TC, Hernandez J, Canby-Hagino ED, Basler JW. Prostate cancer detection strategies Curr Urol Rep 2006 Jan;7:181-185.

Thompson Jr IM, Hernandez J, Basler JW, Mahal, K. Whats new in the field of prostate cancer chemoprevention? Curr Urol Rep 2005 Jan;6:177-182.

Other

Thompson IM, Bermejo C, Hernandez J, Basler JA, Canby-Hagino E. Screening for prostate cancer: opportunities and challenges Surg Oncol Clin N Am 2005 Oct;14(4):747-760.

Mahal K, Hernandez J, Basler J, Thompson IM:. Whats New in the Field of Prostate Cancer Chemoprevention? Curr. Urol. Rep 2005 May;6(3):177-182.

Hernandez J, Basler JW, Thompson IM, Thompson Jr IM. The potential role of cyclooxygenase-2 inhibitors and 5alpha-reductase inhibitors in the prevention of urologic conditions Urol Clin North Am 2004 May;31(2):213-218.

Mahal K, Hernandez J, Basler JW, Thompson IM, Thompson Jr IM. Whats New in the Field of Prostate Cancer Chemoprevention? Curr Oncol Rep 2004 May;6(3):237-242.

Federal
Funding Agency	Southwest Oncology Group
Title	Intermittent Androgen Deprivation Patients with Stage D2 Prostate Cancer
Status	Active
Period	9/1995 - Present
Role	Co-Investigator
Grant Detail
Funding Agency	Veterans Administration Co-Operative Study
Title	Prostate Cancer Intervention Versus Observation Trial (PIVOT): A Randomized Trial Comparing Radical Prostatectomy Versus Palliative Expectant Management for the Treatment of Clinically Localized Prostate Cancer
Status	Active
Period	8/2003 - Present
Role	Principal Investigator
Grant Detail	(study visits) (following 2 patients originally enrolled at other centers)
Funding Agency	Southwest Oncology Group
Title	Adjuvant Androgen Deprivation Versus Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High Risk Prostate Cancer Patients Following Radical Prostatectomy, Phase III
Status	Active
Period	1/2000 - Present
Role	Co-Investigator
Grant Detail
Funding Agency	Southwest Oncology Group
Title	MVAC in Organ-Confined Bladder Cancer Based on p53 Status (012-5011-213)
Status	Active
Period	4/2003 - Present
Role	Co-Investigator
Grant Detail
Funding Agency	National Institute of Health
Title	San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR)
Status	Active
Period	7/2004 - Present
Role	Co-Investigator
Grant Detail
Funding Agency	Southwest Oncology Group
Title	Protocol for Assessment of Gemcitabine and Paclitaxel for Metastatic Urothelial Cancer in patients Ages 70 Years or Older (And in a Cohort of Patients Younger than 60 Years) (012-5011-015)
Status	Active
Period	12/2001 - Present
Role	Co-Investigator
Grant Detail
Funding Agency	National Cancer Institute (EDRN network)
Title	Detection of Bladder cancer by Microsatellite Analysis (MSA) of Urinary Sediment: Multi-Institutional Study
Status	Active
Period	3/2004 - Present
Role	Co-Investigator
Grant Detail
Funding Agency	Southwest Oncology Group
Title	Intergroup Phase III Randomized Trial Comparing Total Androgen Blockage versus Total Androgen Blockade plus Pelvic Irradiation in Clinical Stage T3-4, N0, M0 Adenocarcinoma of the Prostate
Status	Active
Period	3/1997 - Present
Role	Co-Investigator
Grant Detail
Funding Agency	Southwest Oncology Group
Title	L-Selenium-Based Chemoprevention of Prostate Cancer Among Men With High Grade Prostatic Intraepithelial Neoplasia
Status	Active
Period	5/2000 - Present
Role	Co-Investigator
Grant Detail
Private
Funding Agency	Antigenics
Title	A Multi-Center, Randomized Phase III Study of Adjuvant Oncophage vs Observation in Patients with High Risk of Recurrence After Surgical Treatment for Renal Cell Carcinoma
Status	Complete
Period	9/2005 - Present
Role	Co-Investigator
Grant Detail
Funding Agency	Pfizer
Title	A Randomized, Double-Blind, Placebo Controlled, Four Arm (Placebo, Tolterodine ER, Tamsulosin, and Tolterodine ER Plus Tamsulosin) Study to Evaluate The clinical Efficacy and Safety of Tolterodine ER 4 mg In Men who Have Frequency and Urgency, with or wi
Status	Active
Period	11/2004 - Present
Role	Co-Investigator
Grant Detail
Funding Agency	Glaxo SmithKline
Title	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5mg Administered Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer
Status	Active
Period	8/2003 - Present
Role	Co-Investigator
Grant Detail
Funding Agency	Abbott Laboratories
Title	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 10 mg Atrasentan in Men with non-Metastatic, Hormone-Refractory Prostate Cancer
Status	Complete
Period	3/2002 - Present
Role	Principal Investigator
Grant Detail	(one patient in survival follow-up at Cancer Therapy and Research Center)
Funding Agency	GSK
Title	A Randomized, Double-Blind, Parallel Group Study to Investigate the Efficacy and Safety of Treatment with Dutasteride (0.5mg) and Tamsulosin (0.4mg), Administered Once Daily for 4 Years, Alone and in Combination, on the Improvement of Symptoms and Clinic
Status	Active
Period	8/2003 - Present
Role	Co-Investigator
Grant Detail	Closed to accrual 12/2004
Funding Agency	Guilford Pharmaceuticals, Inc.
Title	Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 3 Arm, 12 Month Study to Evaluate the Effects of GPI 1485 on Erectile Function in Patients Undergoing Bilateral Nerve-Sparing Radical Retropubic Prostatectomy for Prostatic Carcinoma (0
Status	Active
Period	9/2003 - Present
Role	Co-Investigator
Grant Detail	Closed to accrual 03/2005

Funding Agency	Early Detection Research Network
Title	Identification of Protein and Genetic Biomarkers of Prostate Cancer and Risk Factors for Progression of Disease.
Status	Active
Period	3/2000 - Present
Role	Co-Investigator
Grant Detail
Funding Agency	Non-funded
Title	Establishment of a Bladder Cancer Data Base in South Texas
Status	Active
Period	2/2005 - Present
Role	Co-Investigator
Grant Detail
Funding Agency	Center for Disease Control
Title	A Prospective Study on the Effect of Treatment on Health-Related Quality of Life for Men with Localized Prostate Cancer
Status	Active
Period	9/2005 - Present
Role	Co-Investigator
Grant Detail
Funding Agency	Non-funded
Title	Biomarker Discovery for Renal Cell Carcinoma Through Serum, Urine and Tissue Protein Profiles
Status	Active
Period	3/2004 - Present
Role	Co-Investigator
Grant Detail

Year	Degree	Discipline	Institution
1990	Residency	Urology	Washington University School of Medicine - Barnes Hospital Saint Louis , MO
1986	Residency	Surgery	University of Missouri Columbia , MO
1984	MD	Medicine	University of Missouri Columbia , MO
1983	PhD	Molecular Biology	State University of New York Buffalo , NY
1979	MA	Molecular Biology	State University of New York Buffalo , NY
1976	MA	Biology	University of Missouri Columbia , MO
1974	BA	Biology	University of Missouri Columbia , MO

Date	Description	Institution	# Students
1/2006 - Present	Post-Doctoral Student Supervision	UTHSCSA Department of Urology

9/1998 - Present	Surgery Clerkship	The University of Texas Health Science Center
Student Conferences MS-3, MS-4
9/1998 - Present	Intro to Clinical Surgery	The University of Texas Health Science Center
MS - 2 Lectures
9/1998 - Present	Post-Doctoral Student Supervision	University Hospital, VA Hospital, SRNW

Faculty

FAQ

Suggestions

Basler, MD, Joseph W

Endourology

Urologic Oncology